DBV Technologies reported $235.6M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 172.31M 174K Sep/2026
Alnylam Pharmaceuticals USD 133.88M 141K Sep/2026
Amarin USD 20.81M 13K Dec/2025
BioCryst Pharmaceuticals USD 255.26M 42.2M Jun/2026
BioMarin Pharmaceutical USD 193.68M 141K Sep/2026
DBV Technologies USD 235.6M 98.78M Dec/2025
Galectin Therapeutics USD 61K 0 Dec/2023
Halozyme Therapeutics USD 113.94M 106K Sep/2026
Incyte USD 200.98M 1.03M Jun/2026
Insmed USD 218.28M 1.76M Jun/2026
Ionis Pharmaceuticals USD 166.41M 773K Sep/2026
Neurocrine Biosciences USD 101.3M 750K Sep/2026
PTC Therapeutics USD 83.33M 445K Jun/2026
Sarepta Therapeutics USD 107.23M 1.61M Sep/2026
Ultragenyx Pharmaceutical USD 98.6M 300K Jun/2026
United Therapeutics USD 42.38M 295K Sep/2026